Annual non-GAAP net income and non-GAAP EPS was $4.1bn and $4.54, up 36% and 35%, respectively, compared to 2009.
For the fourth quarter, non-GAAP net income and non-GAAP EPS was $1.1bn and $1.25, up 35% and 33% respectively, compared with the same period in 2009.
Teva said the announced results show a record global in-market sales of Copaxone of $3.3bn in the year ended 2010, a 17% hike compared to 2009, and a record annual cash flow from operations of $4.1bn (a $3.4bn increase from 2009).
Teva president and CEO Shlomo Yanai said 2010 has been a great year for Teva, in which the company delivered record-breaking results across all its geographies while strengthening and expanding its global leadership.